Records documenting symptoms, diagnosis, treatment history, and the timing of medication use can help establish whether complications developed after exposure to semaglutide or tirzepatide medications
However, the viability of the bacteria is unknown, and this is a subject for further study
As research in this field continues to evolve, ongoing and future CVOTs will likely expand our knowledge of the cardiovascular benefits of GLP-1 receptor agonists, ultimately improving the care and outcomes of individuals with T2D and CVD
GLP-1 medications can help: Weight loss from these medications reduces sleep apnea severity Studies show they can reduce the Apnea-Hypopnea Index (AHI) by 12-15 events per hour Tirzepatide reduced AHI by 48-56% compared to placebo Since OSA is both a cause and consequence of other health problems, improving sleep breathing can create a cascade of health benefits
People Seeking Either Moderation or Abstinence: The medication may support both treatment paths